Top-10 Biotech Companies - Market Outlook, 2008-2023

March 18, 2009 - PRLog -- Report Details
The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970's. The leading healthcare biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other healthcare biotech companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market. Our new report - Top-10 Biotech Companies - Market Outlook, 2008-2023 - will help you to understand those developments and their significance. That report provides valuable commercial information on this exciting industry that no healthcare company should ignore.

Over the period 2008 to 2023, visiongain foresees the healthcare biotechnological market continuing its strong growth, with exciting new developments both technologically and commercially. Increased R&D efforts, shorter approval times and innovative new treatments are aiding market growth. However, the two major threats the healthcare biotechnology sector faces in the coming years are the increasing threat of biogenerics and the difficulty in acquiring capital. Strategic partnerships will continue to be important to biotechnological drug development. There remain significant unmet needs in this market, with great opportunities for companies that can develop safer and better-targeted treatments.

Top-10 Biotech Companies - Market Outlook, 2008-2023 examines the product portfolios of the leading companies critically, with in-depth analysis, especially market forecasting and qualitative analysis of market drivers and restraints. The result is a comprehensive market-based report with detailed analysis and informed opinion.

Why you should buy this report:
In particular, Top-10 Biotech Companies - Market Outlook, 2008-2023 concentrates on the following essential aspects of the healthcare biotech market:
• Achievements and aspirations of global healthcare biotechnology
• Detailed sales forecasts from 2008-2023 for the sector, leading biotech companies and their main products
• Issues affecting the sector
• Discussion of drivers and opportunities
• Discussion of restraints and threats
• Detailed analyses of the top-10 healthcare biotech companies from 2008 onwards
• Salient pipeline developments in biotechnology and their implications for the future.

In 2007, the global revenues generated by the top-10 biotech companies exceeded $45bn. Amgen, Genentech and UCB are good examples of leading companies that have experienced strong sales growth in recent years. Principal drugs developed and marketed by the leading companies include Aranesp, Mabthera and Keppra, each with blockbuster sales. Moreover, pipelines of the leading biotech companies remain strong.

The leading healthcare biotechnology companies will continue to make strong inroads into the overall global pharma industry and market in the years ahead, with rising stars competing too. Do you know how sales of leading biotech companies will develop over the coming years? Do you know the prospects for other biotech organisations? Visiongain concludes that there will be increasing reliance on biological drugs as time goes by, especially for recalcitrant diseases with significant unmet needs. The commercial and technological opportunities for greater personalisation of medicine through biotechnology are very exciting. Certainly, the commercial opportunities for dynamic healthcare biotech companies are significant. The development of more-personalised medicine promising greater efficacy and safety - particularly in cancer treatment - is a major commercial hope. By purchasing this report, you will be better prepared to appreciate those major developments in the global pharmaceutical market.

Companies Listed
Abbott
Abgenix
Actelion
Amgen
Anthrogenesis
AstraZeneca
Biogen Idec
Bristol-Myers Squibb
Cardiokine Biopharm
Celera Genomics
Celgene
Cephalon
Chugai
CoTherix
CSL Ltd
CuraGen
Eisai
Eli Lilly
EMEA
FDA
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline (GSK)
Human Genome Sciences
Immunex-
Incyte Genomics
Iomai Corporation
Johnson & Johnson (J&J)
MedImmune
Merck KGaA
MGI
Millennium Pharmaceuticals
Mundipharma
Myriad Genetics
Novartis
Novo Nordisk
Pfizer
Pharmion
Roche
Roche Centre for Medical Genomics (RCMG)
Sanofi-Aventis
Schering-Plough
Schwarz Pharma
Serono (now Merck Serono)
Signal Pharmaceuticals
Teva
UCB
US Congressional Budget Office (CBO)
Ventana Medical Systems
World Health Organisation (WHO)
Wyeth
Zenyaku

Visiongain ltd.
4th Floor,
BSG House,
226-236 City Road,
London
EC1V 2QY
United Kingdom

Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=355
Or http://www.visiongain.com

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.